Elsevier

Kidney International

Volume 75, Issue 8, 2 April 2009, Pages 800-808
Kidney International

Original Article
Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure

https://doi.org/10.1038/ki.2008.690Get rights and content
Under an Elsevier user license
open archive

Chronic kidney disease is often complicated by uremic cardiomyopathy that consists of left ventricular hypertrophy and interstitial fibrosis. It is thought that hypertension and volume overload are major causes of this disease, but here we sought to identify additional mechanisms using a mouse model of chronic renal insufficiency. Mice with a remnant kidney developed an elevated blood urea nitrogen by 1 week, as expected, and showed progressive cardiac hypertrophy and fibrosis at 4 and 8 weeks even though their blood pressures were not elevated nor did they show signs of volume overload. Cardiac extracellular signal-regulated kinase (ERK) was activated in the uremic animals at 8 weeks. There was also an increased phosphorylation of S6 kinase, which is often mediated by activation of the mammalian target of rapamycin (mTOR). To test the involvement of this pathway, we treated these uremic mice with rapamycin and found that it reduced cardiac hypertrophy. Reduction of blood pressure, however, by hydralazine had no effect. These studies suggest that uremic cardiomyopathy is mediated by activation of a pathway that involves the mTOR pathway.

Keywords

blood pressure
rapamycin
uremia
ventricular hypertrophy

Cited by (0)

All the authors declared no competing interests.